ASPIRE-LAKEWOOD HOLDINGS INC

ASBPNASDAQ

🏆 #5422 by market capUS Equity

$573.63▲ $14.46 (+2.52%)

Simulated price

🔔

Track ASBP

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.5%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$980,662

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

18.4%

Thin

💵FCF Margin

-7358.2%

Thin

⚖️P/S Ratio

10.0x

Elevated

Otter Score

Fair

No chart data available for ASBP.

Trading Snapshot

Day Range: $566.53 – $583.25
52-Week Range: $0.11 – $562.80
Volume: $3.04B
Avg Volume: $2.36B
Shares Outstanding: 115,372
Next Earnings: Nov 15, 2026

Fundamentals Snapshot

Annual Revenue: $6,202
Last Q Revenue: $63,103
P/E Ratio: -1.1
P/S Ratio: 10.0x
EPS (TTM): $-10.65
Dividend Yield: 0.00%
Dilution (1yr): +6399.8%

Why Investors Own ASBP

✓High-growth profile — revenue up +42.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ASPIRE-LAKEWOOD HOLDINGS INC

ASBP

Financial Trends

Revenue

$6K▲ +0.0% YoY

Operating Income

−$19M▲ +1498.1% YoY

Free Cash Flow

−$5M▲ +1756.6% YoY

Shares Outstanding

1.5M▲ +6399.8% YoY

Net Cash

−$4M▼ −$3M YoY

StockOtter · stockotter.space

About ASPIRE-LAKEWOOD HOLDINGS INC

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

🦦